Clinical Scorecard: Parabilis Sets Biotech IPO Record
At a Glance
| Category | Detail |
|---|---|
| Condition | Cancer and related conditions |
| Key Mechanisms | Stabilized helical peptides targeting protein modulation |
| Target Population | Patients with desmoid tumors, familial adenomatous polyposis, hepatocellular carcinoma, and other solid tumors with Wnt pathway-activating mutations |
| Care Setting | Clinical-stage biotechnology |
Key Highlights
- Raised $670 million in IPO, setting a new biotech listing record on Nasdaq
- Sold 33.5 million shares at $20 per share, trading under ticker PBLS
- Private placement with Regeneron for 4,166,666 shares at $18 per share
- Total expected gross proceeds of approximately $745 million
- Developing zolucatetide targeting beta-catenin in the Wnt/beta-catenin pathway
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with specific solid tumors and genetic conditions
Zolucatetide is in development for multiple indications related to Wnt pathway mutations
Clinical Best Practices
- Utilize stabilized helical peptides for difficult-to-drug protein targets
- Consider collaboration opportunities for advancing clinical programs
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
